Overview

Dr. Shizuo Mukai is a clinician scientist with clinical expertise in the surgical and medical management of vitreoretinal diseases, including complex retinal detachments, pediatric retina, intraocular tumors of the posterior segment (especially retinoblastoma), genetic retinal diseases, and retinal imaging.

Departments

Ophthalmology

Clinical Interests
  • Retina
  • Retinopathy of prematurity
  • Ocular oncology
Medical Education
  • MD, Brown University School of Medicine
  • Residency, Massachusetts Eye and Ear Infirmary
  • Fellowship, Massachusetts Eye and Ear Infirmary
Board Certifications
  • Ophthalmology
Foreign Languages
  • Japanese
Locations
  • Boston: Massachusetts Eye and Ear Infirmary
  • Boston: Massachusetts General Hospital
Insurances Accepted
  • Blue Cross Blue Shield - Blue Care 65
  • Blue Cross Blue Shield - Indemnity
  • Blue Cross Blue Shield - Managed Care
  • Blue Cross Blue Shield - Partners Plus
  • Harvard Pilgrim Health Plan - other
  • Senior Whole Health
  • Tufts Health Plan

Note: This provider may accept more insurance plans than shown; please call the practice to find out if your plan is accepted.

Patient Age Group
Adult
Gender
Male

Edit Profile

Biography

Dr. Shizuo Mukai is a clinician scientist with clinical expertise in the surgical and medical management of vitreoretinal diseases, including complex retinal detachments, pediatric retina, intraocular tumors of the posterior segment (especially retinoblastoma), genetic retinal diseases, and retinal imaging.

Dr. Mukai earned his degree in medicine from Brown University School of Medicine. After completing a research fellowship in Molecular Genetics and Eye Pathology, an Ophthalmology residency, and a joint clinical and research fellowship in Retina and Molecular Genetics, all at Mass. Eye and Ear, Dr. Mukai joined the Retina Service in 1989.

Edit Profile

Research & Publications

Research Summary

Dr. Mukai's research interests include molecular biology of retinal diseases (especially retinoblastoma) and proliferative vitreoretinopathy, new treatment approaches to retinoblastoma, smartphone-based retinal imaging and computerized image analysis, phenotype-genotype correlations in genetic retinal conditions, and retinal stem cells.

Publications

View my most recent publications at PubMed

Daniels AB, Jakobiec FA, Westerfeld CB, Hagiwara A, Michaud N, Mukai S. Idiopathic subfoveal choroidal neovascular membrane in a 21-month-old child: ultrastructural features and implication for membranogenesis. J AAPOS. 2010 Jun; 14(3): 244-50.

Vavvas D, Kim I, Lane AM, Chaglassian A, Mukai S, Gragoudas E. Posterior uveal melanoma in young patients treated with proton beam therapy. Retina. 2010 Sep; 30(8): 1267-71.

Lei H, Rheaume MA, Velez G, Mukai S, Kazlauskas A. Expression of PDGFRα is a determinant of the PVR potential of ARPE19 cells. Invest Ophthalmol Vis Sci. 2011 Aug; 52(9): 5016-21.

Conkrite K, Sundby M, Mukai S, Thomson JM, Mu D, Hammond SM, MacPherson D. miR-17|92 cooperates with RB pathway mutations to promote retinoblastoma. Genes Dev. 2011 Aug 15; 25(16): 1734-45.

Pennock S, Rheaume MA, Mukai S, Kazlauskas A. A novel strategy to develop therapeutic approaches to prevent proliferative vitreoretinopathy. Am J Pathol. 2011 Dec; 179(6): 2931-40.

Edit Profile

News & Events

  • A second chance

    MGH Hotline 07.30.10 Th efforts of three doctors at three separate institutions came together to forever change the life of one little boy living in a remote village in Haiti.

Contact

Massachusetts Eye and Ear Infirmary
243 Charles Street
Boston MA, 02114 - 3002
Phone: 617-573-3730

Edit Profile